Top Markets
#1 Black Phoenix Black Phoenix +732.64%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +24.80%
#3 TENDIES TENDIES +22.99%
#4 THORChain THORChain +18.96%
#5 Biconomy Biconomy +18.30%
#6 MetaDAO MetaDAO +16.83%
#7 Wrapped STX (Velar) Wrapped STX (Velar) +16.29%
#8 Pons Pons +16.01%
#9 Moolah Moolah +15.93%
#10 THORChain Yield THORChain Yield +13.92%
Coin of the day
Black Phoenix Black Phoenix
設定
言語
日本
通貨
USD
テーマ
Zai Lab Limited Zai Lab Limited

Zai Lab Limited

ZLAB
株式のランク #5163
Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a... Operating primarily in Mainland China and Hong Kong, Zai Lab Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medical treatments. Their therapeutic portfolio spans oncology, autoimmune conditions, infectious diseases, and neurological disorders. Currently available products in their portfolio include Zejula, a once-daily small-molecule PARP 1/2 inhibitor; Optune, a medical device leveraging tumor treating fields; NUZYRA, an antimicrobial agent for specific acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia; and Qinlock, indicated for gastrointestinal stromal tumors. Beyond its commercial offerings, Zai Lab boasts an extensive pipeline of investigational therapies. These include Odronextamab for various B-cell lymphomas; Repotrectinib, a tyrosine kinase inhibitor targeting ROS1 and TRK pathways in both TKI-naïve and pretreated cancer patients; Margetuximab for breast and gastroesophageal cancers; Adagrasib for KRAS-G12C-mutated solid tumors like NSCLC, colorectal, and pancreatic cancers; and Bemarituzumab for gastric and gastroesophageal junction cancers. Further pipeline candidates encompass CLN-081 for EGFR exon 20 insertion NSCLC; Elzovantinib, an orally available multi-targeted kinase inhibitor; Tebotelimab, a tetravalent IgG4 monoclonal antibody; Retifanlimab, designed to block PD-1 interactions with its ligands; ZL-2309, an orally active and selective CDC7 kinase inhibitor; ZL-1201, a humanized IgG4 monoclonal antibody; Efgartigimod, aimed at reducing pathogenic immunoglobulin G antibodies; ZL-1102, a human nanobody against interleukin-17A; KarXT for psychiatric and neurological conditions; ZL-2313 and ZL-2314, both investigational EGFR inhibitors targeting specific mutations; and Sulbactam/durlobactam, intended for serious infections caused by Acinetobacter. Established in 2013, Zai Lab Limited maintains its corporate headquarters in Shanghai, China.
株価
$26.03
最終同期: 2026-08-26
時価総額
$2.94B
変化（1日）
-0.55%
変化（1年）
-20.07%
国
CN
取引 Zai Lab Limited (ZLAB)

カテゴリー

Healthcare
Zai Lab Limited（ZLAB）の株価履歴
終値の最高値: $25.27 （2026-08-01）

終値の最安値: $27.89 （2017-09-01）
Zai Lab Limited の株価履歴（2017 ～ 2026）
年間株価パフォーマンス
年 パフォーマンス
2026 (TTM) 19.83%
2025 -32.96%
2024 -1.60%
2023 -15.44%
2022 -50.77%
2021 -44.11%
2020 193.25%
2019 87.31%
2018 -9.94%
2017 0.00%
類似企業または競合の株価
企業 株価 変化率 1年% 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $549.38 41.20%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.05K 47.75%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $148.35 491.02%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $122.41 -12.81%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $764.47 7.08%
CH